Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Selgantolimod · 2 trials · 1 indication
An AE was any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. An AE was any unfavorable and unintended sign, symptom, disease, and/or laboratory or physiological observation that may or may not be related to the investigational medicinal product. A TEAE was defined as any AE with an onset date on or after the first dose date and no later than 30 days after permanent discontinuation of selgantolimod/placebo; or any AE leading to premature discontinuation of study drugs.
Treatment-emergent laboratory abnormalities were defined as values that increased at least 1 toxicity grade from baseline at any postbaseline time point, up to and including the date of the last dose of study drug plus 30 days for selgantolimod/placebo at Week 24. If the relevant baseline laboratory value was missing, any abnormality of at least Grade 1 observed within the time frame specified above was considered treatment emergent. Clinical laboratory results were graded according to Gilead Grading Scale for Severity of Adverse Events and Laboratory Abnormalities.
| Arm | Type | Description |
|---|---|---|
| Selgantolimod 3 mg + TAF | EXPERIMENTAL | Participants with Hepatitis B e antigen (HBeAg)-positive CHB or HBeAg-negative CHB currently not on oral antiviral (OAV) treatment, will receive selgantolimod 3 mg (2 x 1.5 mg tablet) on the same day once weekly for 24 doses along with tenofovir alafenamide (TAF) 25 mg once daily for 24 weeks. After the 24th dose, selgantolimod will be discontinued, and participants will continue to receive TAF until Week 48/early discontinuation (ED). At Week 48, per Principal Investigator's (PI's) discretion, participants can continue in the Treatment Free Follow-Up (TFFU) phase for up to an additional 48 weeks. |
| Selgantolimod 1.5 mg + TAF | EXPERIMENTAL | Participants with HBeAg-positive CHB or HBeAg-negative CHB currently not on OAV treatment, will receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) and placebo (1 tablet) on the same day once weekly for 24 doses along with TAF 25 mg once daily for 24 weeks. After the 24th dose, selgantolimod will be discontinued, and participants will continue to receive TAF until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks. |
| Placebo + TAF | PLACEBO_COMPARATOR | Participants with HBeAg-positive CHB or HBeAg-negative CHB currently not on OAV treatment, will receive 2 tablets of placebo on the same day once weekly for 24 doses along with TAF 25 mg once daily for 24 weeks. After the 24th dose, placebo will be discontinued, and participants will continue to receive TAF until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks. |
| Selgantolimod 3 mg: HBeAg-positive CHB Participants | EXPERIMENTAL | Participants with Hepatitis B e Antigen (HBeAg)-positive CHB will remain on their current OAV and receive selgantolimod 3 mg (2 x 1.5 mg tablet) orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/early discontinuation (ED). At Week 48, per Principal Investigator's (PI's) discretion, participants can continue in the Treatment Free Follow-Up (TFFU) phase for up to an additional 48 weeks. |
| Selgantolimod 3 mg: HBeAg-negative CHB Participants | EXPERIMENTAL | Participants with HBeAg-negative CHB will remain on their current OAV and receive selgantolimod 3 mg (2 x 1.5 mg tablet) orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks. |
| Selgantolimod 1.5 mg: HBeAg-positive CHB Participants | EXPERIMENTAL | Participants with HBeAg-positive CHB will remain on their current OAV and receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) plus 1 tablet of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks. |
| Selgantolimod 1.5 mg: HBeAg-negative CHB Participants | EXPERIMENTAL | Participants with HBeAg-negative CHB will remain on their current OAV and receive selgantolimod 1.5 mg (1 x 1.5 mg tablet) plus 1 tablet of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks. |
| Placebo: HBeAg-positive CHB Participants | EXPERIMENTAL | Participants with HBeAg-positive CHB will remain on their current OAV and receive 2 tablets of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks. |
| Placebo: HBeAg-negative CHB Participants | EXPERIMENTAL | Participants with HBeAg-negative CHB will remain on their current OAV and receive 2 tablets of placebo orally on the same day once a week (every 7 days) for 24 doses. After the 24th dose, participants will continue their current OAV therapy until Week 48/ED. At Week 48, per PI's discretion, participants can continue in the TFFU phase for up to an additional 48 weeks. |
| Name | Type | Description |
|---|---|---|
| Placebo | DRUG | Tablet(s) administered orally every 7 days for 24 doses in fasted state |
| Selgantolimod | DRUG | Tablet(s) administered orally every 7 days for 24 doses in fasted state |
| TAF | DRUG | Tablet(s) administered orally once daily with food |
| Hepatitis B virus (HBV) OAV Therapy | DRUG | Commercially available HBV OAV therapy could include one of the following: Tenofovir disoproxil fumarate (TDF; Viread®) Entecavir (Baraclude®) Adefovir (Hepsera®) Lamivudine (Epivir® ) Telbivudine (Tyzeka®) Tenofovir alafenamide (TAF; Vemlidy®) |
Key Inclusion Criteria: * Must have the ability to understand and sign a written informed consent form, which must be obtained prior to initiation of study procedures. * Adult male and non-pregnant, non-lactating females * Documented evidence of chronic hepatitis B virus (HBV) infection with detect...
GS-4774 is an investigational therapeutic being studied for chronic hepatitis B and chronic HBV infection. It was evaluated in a Phase 1 trial in healthy volunteers and a Phase 2 trial in patients with chronic HBV infection. Both trials have been completed.
GS-4774 is being developed by Gilead Sciences, Inc. (NASDAQ: GILD). The company has completed two clinical trials of the drug, including a Phase 2 study in chronic hepatitis B.
GS-4774 has completed Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. Two trials, one Phase 1 and one Phase 2, have been completed with a total enrollment of 178 participants.
GS-4774 has been studied in two completed trials: NCT01779505, a Phase 1 trial in healthy volunteers, and NCT01943799, a Phase 2 trial for chronic HBV infection. Both trials were conducted in the United States, with the Phase 2 trial also including New Zealand.
Yes, GS-4774 is also known as GI-13020. The Phase 1 trial NCT01779505 assessed the safety, tolerability, and immunogenicity of GS-4774 (GI-13020) at various dose levels and regimens in healthy adults.